📣 PTC Therapeutics Informa:

Actualización para la Comunidad Duchenne en EE. UU. sobre la revisión de la solicitud de registro de nuevo fármaco de Ataluren (Translarna™)

#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #duchenneenespañol #PTCTherapeutics #Ataluren #Translarna

PTC pulls file for Duchenne therapy on FDA feedback PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy treatment Translarna.

#PTCTherapeutics has abandoned its latest attempt to secure #FDA approval for #Duchenne muscular dystrophy (DMD) treatment #Translarna, after the FDA said it was unlikely to approve the drug based on the submitted data.

PTC Therapeutics Takes Step Back on Translarna™ Regulatory Submission Following FDA Feedback PTC Therapeutics Inc. announces the withdrawal of the NDA for Translarna, aimed at treating Duchenne muscular dystrophy, following negative FDA feedback.

PTC Therapeutics Takes Step Back on Translarna™ Regulatory Submission Following FDA Feedback #USA #PTC_Therapeutics #Warren #Duchenne_Muscular_Dystrophy #Translarna

PTC Therapeutics: Regulatory Developments for Translarna in Europe Raise Concerns PTC Therapeutics announced the European Commission's decision not to renew Translarna’s marketing authorization, raising challenges for Duchenne muscular dystrophy treatments. Individual nations may still allow usage.

PTC Therapeutics: Regulatory Developments for Translarna in Europe Raise Concerns #United_States #PTC_Therapeutics #Warren,_NJ #Duchenne_Muscular_Dystrophy #Translarna

PTC Therapeutics Delivers Solid Financial Performance in 2024 with Key Growth Strategies for 2025 PTC Therapeutics reports its robust financial results for 2024, showcasing significant revenue growth and strategic collaborations to enhance future prospects.

PTC Therapeutics Delivers Solid Financial Performance in 2024 with Key Growth Strategies for 2025 #United_States #PTC_Therapeutics #Warren,_New_Jersey #Huntington's_Disease #Translarna